CLL or small lymphocytic lymphoma
Haematology · 2023–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| zanubrutinib Treatment of previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients unsuitable for fludarabine-based… | Mar 2023 | Recommended with restriction | 1 individuals Rare Cancers Australia · Lymphoma Australia · Leukaemia Foundation |
Who spoke
Rare Cancers Australia · Lymphoma Australia · Leukaemia Foundation
What the PBS pays
$136M in government benefit over 2024–25, across 17,241 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| zanubrutinib | $136.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.